Meta-Analysis of Randomized Trials: Efficacy and Safety of Colchicine for Secondary Prevention of Cardiovascular Disease

Table 2

Patient characteristics at baseline.

Study	Raju et al.		Deftereos et al.		LoDoCo		COLIN		LoDoCo-MI		COLCOT		LoDoCo-2		COPS
	Colchicine	Placebo	Colchicine	Placebo	Colchicine	Placebo	Colchicine	Placebo	Colchicine	Control	Colchicine	Placebo	Colchicine	Placebo	Colchicine	Nonexposed
Number of patients	40	40	100	96	282	250	23	21	119	118	2366	2379	2762	2760	396	399
Mean age (y)	57.2	57.2	63.7	63.5	66	67	60.1	59.7	61	61	60.6	60.5	65.8	65.9	59.7	60.0
Male (%)	85	93	63	68	89	89	82.5	76.2	75	79	80.1	81.6	83.5	85.9	81	78
Diabetes (%)	18	15	100	100	33	28	13.0	14.3	23	21	19.5	20.9	17.8	18.7	19	19
Hypertension (%)	48	38	48	49	—	—	39.1	47.6	54	41	50.1	52	51.4	50.3	51	50
Smoker (%)	45	43	36	40	4	6	73.9	66.7	65	57	29.9	29.8	11.5	12.0	32	37
Medications (%); Aspirin	100	100	—	—	93^1	94^1	-^2	-^2	99	100	98.6	98.9	66.9	67.1	99	98
Statin	100	95	—	—	96	94	—	—	97	100	98.9	99.1	93.9	94.0	98	99
ACEI/ARB	—	—	—	—	55	60	—	—	96	92	—	—	72.2	71.2	88	86
Beta-blocker	—	—	—	—	62	71	—	—	93	92	89.4	88.3	61.3	62.9	81	85

ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker. ¹Aspirin and/or clopidogrel. ²As per authors, all patients received aspirin at the time of primary PCI, but the percentage of patients that remained on aspirin in each arm is not stated.